

Date of Submission: 29th May 2017

To

Secretary

Listing Department

BSE Limited

Department of Corporate Services

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai - 400 001

Scrip Code - 539551

To

Secretary

Listing Department

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex

Mumbai - 400 050

Stock Code- NH

Dear Sir/Madam,

Sub: Investor Presentation for FY 2016-17.

With reference to the captioned subject, please find enclosed Investor Presentation for FY 2016-17 ending 31st March, 2017.

Kindly take the above said information on record as per the requirement of Listing Regulations.

Thanking You,

Yours faithfully

For NARAYANA HRUDAYALAYA LIMITED

Scidhar S.

Group Company Secretary, Legal and Compliance Officer

Encl: A/A





Investor Presentation
May 2017

Important Disclosure

No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of this date. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements", including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects, and future developments in its industry and its competitive and regulatory environment.

Actual results may differ materially from these forward-looking statements due to a number of factors, including future changes or developments in the Company's business, its competitive environment and economic, legal and social conditions in India.

This communication is for general information purpose only, without regard to specific objectives, financial situations and needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any shares in the Company and neither any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation can not be copied and/or disseminated in any manner.

The NH Case





Leading Pan-India Multispeciality Healthcare Group

As on 1st May 2017



51	Healthcare Facilities	re Facilities Operational beds		
20	Owned / Operated Hospitals ⁽¹⁾	4,721 Beds		
4	Managed Hospitals ⁽²⁾	720 Beds		
7	Heart Centres	376 Beds		
19	Primary Healthcare Facilities ⁽³⁾	10 Beds		
1	Hospital in Cayman Islands	105 Beds		



7,181	Capacity Beds
5,932	Operational Beds
2.7 mn ⁽⁴⁾	Average Effective Capital Cost per Operational Bed



Specialities



Daily Average Surgeries and Procedures



14.330

30+

343⁽⁵⁾


Full-time Employees and Associates including 3,011 doctors

- (1) NH owns the P&L responsibility
- (2) NH manages 3rd party hospitals for Management Fees
- (3) Includes clinics, information centres, etc
- (4) Based on (Gross Block for Fixed Assets (adjusted for non-cash government grant provision) + Capital Work in Progress (CWIP)) / Number of operational beds as of 31st Mar 2017. excludes Managed Hospitals and Cayman facility
- (5) Daily average calculated on a 365 days basis for FY17; excludes Vaishno Devi unit

NH's footprint in India



Evolution of India's Second Largest* Healthcare Operator



"Proof of concept" for affordable healthcare business case

2000 - 2007

- Humble beginning with focus on cardiac only services
- Presence limited to only 2 hospitals across
 Bengaluru & Kolkata

2008 - 2012

- Broadened the service offering by opening multispeciality hospitals across the country viz. Jamshedpur, Jaipur, Raipur and Ahmedabad
- Leveraged the brand expertise and started operating Heart Centres in third party hospitals
- JP Morgan and AIG invested US\$100 mn in 2008

2013 - 2015

- Focus on "Asset-Right" Model viz.
 Shimoga, Whitefield, HSR,
 Guwahati facilities
- Growth through inorganic route -Acquisition of MMRHL and Barasat facilities at Kolkata
- Entered into international market by setting up a facility at Cayman Islands
- Raised US\$48 mn from CDC in 2014

- Listed successfully on bourses and touched US\$1 bn Market Cap
- Forayed into Northern India with commissioning of super speciality hospital in Kakriyal, Jammu
- Bolstered the Northern cluster by entering NCR region through Dharamshila Narayana Hospital and an upcoming hospital in Gurugram
- Maiden entry into Mumbai to strengthen the Western Cluster with a unique superspeciality Children's Hospital - first of its kind in NH network

* By operational bed count as of 1st May 2017



Best-in-Class Leadership with Diverse Experience



Dr. Devi Prasad Shetty

Chairman and Executive Director

- Cardiac surgeon with 33 years of experience
- Conferred 'Padma Shri' and 'Padma Bhushan' Award in 2003 and 2012, respectively



Dr. Ashutosh Raghuvanshi Vice Chairman, MD & CEO

- Cardiac surgeon with 26 years of experience
- Post-graduation in cardiac surgery from the University of Bombay



Viren Shetty

Executive Director

- MBA from Stanford University
- 8 years of experience



Kiran Mazumdar Shaw Non-Executive Director

- Chairperson and MD of Biocon
- 39 years of experience



Dinesh Krishna Swamy Independent Director

- Founding member of Infosys Limited
- 34 years of experience



Muthuraman Balasubramanian **Independent Director**

- Ex VC of Tata Steel & conferred 'Padma Bhushan' Award in 2012
- 43 years of experience



Arun Seth Independent Director

- Board member of Jubilant Food Works, Centum Learning, Usha Breco and Samtel Avionics
- Trustee of the Nasscom Foundation



B.N. Subramanya **Independent Director**

- Member of the Indian Institute of Chartered Accountants
- 30 years of experience




Manohar D Chatlani Independent Director

- Proprietor of the Men's Favorite Shop, part of MD Retail
- 40 years of experience



Distinguished Capital Outlay Framework Underpins Emphasis on Return Metrics

- Flexible Business Models to maximize returns
- Average Effective Capital Cost per bed of ₹ 2.7 million⁽¹⁾
- "Asset-Right" Model partners own the fixed assets, NH owns the medical equipment and operates & manages the hospital
- Hospitals Addition since 1st April 2013⁽²⁾
 - ➤ 10 hospitals + 2 heart centres (2,162 capacity beds)
 - ➤ 3 acquired facilities (577 capacity beds)
- Preferred Partner owing to scale, track-record, and ethos of high quality affordable care



⁽¹⁾ Based on (Gross Block for Fixed Assets (adjusted for non-cash government grant provision) + Capital Work in Progress (CWIP)) / Number of operational beds as of 31st Mar 2017. excludes Managed Hospitals and Cayman facility

⁽²⁾ Excluding Cayman facility, Kuppam, Suguna and Hyderabad, Berhampore facilities

⁽³⁾ Includes NICS, MSMC, Barasat, 2 MMRHL units, Ahmedabad, Jaipur, Mysore facilities

⁽⁴⁾ Includes RTIICS, Jamshedpur, Raipur, Shimoga, HSR, Whitefield, RNN, NSC, SRCC, Dharamshila facilities


⁽⁵⁾ Includes Palanpur, JSW Bellary, Mahuva and Durgapur IQ City

⁽⁶⁾ Includes Jammu, Guwahati facilities



Evolving Case Mix with Leadership in Cardiac & Renal Sciences and Growing Share of Other Specialities

De-risking business model by expanding the service spectrum⁽¹⁾





Cardiac and Renal Sciences

- The department of cardiology carried out the first Transcatheter Aortic
 Valve Implantation (TAVI) in India
- ~35,000 angiogram, ~12,000 angioplasty, ~2.25 Lacs dialysis sessions conducted in FY17
- Performed 35 heart transplants and 2,976 renal transplants till date



Oncology

- NH operates one of the largest Bone Marrow Transplants unit in the country with over 160 BMTs done in FY17
- NH's unit at Howrah is recognized as the Centre for Excellence in the field of Oncology



Gastro Intestinal Sciences

- Da Vinci Robotic Surgical program has so far performed over 150 surgeries in last 10 months of commissioning
- NH has started advanced gastroenterology programs at facilities in Mysore and Jaipur
- Performed 72 liver transplants till date



Neuro Sciences

Major emphasis on diseases such as Parkinson's, DBS, Epilepsy treatment



Orthopaedics

 NH delivers specialized care in complex trauma, polytrauma and related sub specialities

Six core specialities contribute 89% to group's revenues



Trusted Brand Decorated with Awards and Recognition

Deep-rooted social & ethical practices coupled with commitment towards clinical excellence

2013(1)





for Industry Architectural Shift



2014-15⁽¹⁾



Asian Hospital Management

Gold Award in the Customer Service



Brand Excellence Award

2014 BCG Local Dynamos Operational Excellence

Indian Health and **Wellness Award** Superspecialty Hospital

State Export Excellence Award

Healthcare Leadership Awards Social Cause

NH's recognition at prominent institutions



Health Brand of the Year









Innovative Marketing Practices

HR Development & Management Award 2016

for Excellence in HR through Technology

Awards & Recognitions for the Chairman

Dr. Devi Shetty



2014	19th Nikkei Asia Prize Economic & Business Innovation
2013	Entrepreneur of the year at ET Awards
2012	Indian of the year by CNN-IBN
2012	The Economic Times Entrepreneur of the Year
2012	Padma Bhushan
2010	Indian of the year by NDTV
2005	Social Entrepreneurship Award
2004	Citizen Extraordinaire, Rotary
2003	Padma Shri
2003	Ernst & Young – Entrepreneur of the Year
2003	Sir M. Visvesvaraya Memorial Award
2002	Rajyotsava Award



















Four Pronged Strategy to Drive Sustained Expansion

One Stop Shop for all Healthcare Needs

- Proven Centre of Excellence in Cardiac and Renal Sciences
- Foster NH's foothold in other specialities
- Focus on becoming a true Pan-India healthcare provider

Adopting Technology, Improving Lives

- Patient well being the centerpiece of the group's vision
- Deploy disruptive technology to foster clinical excellence
- Accomplish the highest degree of surgical precision possible



Leverage upon Operational Synergies

- Affordability is the epicenter of the group's strategy
- Standardize resources and ensure supply chain management to achieve cost efficiencies
- Economies of scale and operating leverage to drive profitability

Tailor-made Engagement Framework

- Ensure optimal utilization of capital
- Maintain a balanced mix of organic and inorganic initiatives
- Nurture an ecosystem of inclusive healthcare

Northern Cluster – Glimpses of Recent Transactions





Realizing the Goal of being a True Pan-India Healthcare Operator

Strategic inroad into Northern region:

NH forayed into northern region of India in April 2016 by commissioning a superspeciality hospital at Kakriyal, Jammu

 Overwhelming response till date with achievement of ~90 occupied beds within first 12 months of operations

Build-out of the cluster:

Derive synergies by expanding presence in Northern India using Kakriyal as a stepping stone

- Growing NCR region as the Hub for the cluster
- Regional feeder units to act as Spokes in the model
- Regional Centres of Excellence, such as, Kakriyal (Jammu)


Minimizing time-to-market:

Entry points in NCR to establish solid foothold in Northern India

Dharamshila Narayana Superspeciality Hospital:

Took over the operations of ~300 capacity bedded running oncology focused hospital in East Delhi





NH Multispeciality Hospital, Gurugram

Acquired a near complete hospital located in Gurugram, South Western region of Delhi





Dharamshila Narayana Superspeciality Hospital: NH's Maiden Foray Into NCR







O&M Arrangement Highlighting "Asset-Light" Engagement:

NH has partnered with Dharamshila Cancer Foundation & Research Centre to operate a ~300 capacity bedded facility in East Delhi

- Deferred payout to the partner over 25 years' timeframe limiting upfront capital outlay
- Significant upside potential with ~50 beds being presently occupied

State-of the-Art Super Speciality Unit:

The oncology focused unit is being upgraded to a state-of the-art super speciality tertiary care unit

Partner is investing in the upgradation work

Minimal Strain on Financials:

Healthy profitability margins with added cost efficiencies as a result of NH's lean operations to help unit deliver satisfactory results

High Degree of Clinical Excellence:

NABH accredited, leading cancer care hospital providing oncology and Bone Marrow Transplantation (BMT) services

• Strong brand recognition for high end cancer treatment in the region

History of Strong Profitable Operations:

It has an operational track record of more than 20 years



NH Gurugram: Emphasizing Group's Commitment to Create a Vibrant Northern Cluster







Strategic Location:

Located on the Delhi-Haryana Border in South West part of NCR

- Proximity to major commercial hubs and thriving residential colonies
- First hospital en route Gurugram from Indira Gandhi International Airport
- This upcoming unit will open the door of opportunities for NH to tap into international patients

Near Complete Hospital :

Substantial civil work already accomplished

- Expected to be commissioned within the next 9 months
- 230 capacity beds with scope to expand up to around 280 beds
- Necessary regulatory approvals in place

Attractive Transaction Economies:

Acquisition at discount to capital invested in the project

Infrastructure at Par with International Standards:

The hospital is envisaged to have top-notch standard of care and safety with best-in-class medical equipment and civil infrastructure

Commissioning of SRCC Children's Hospital in Mumbai





SRCC Children's Hospital: Inroad in Mumbai with a Unique "Children's Only" Hospital







Premier "One-of-its-Kind" Paediatric Facility:

First of its kind in NH's network

- The hospital is envisaged to leverage the strong credentials NH has developed in Paediatric care
 - NH operates one of the World's largest paediatric cardiac care unit at its Health City, Bengaluru
- 207 capacity bedded facility, to offer all the paediatric super specialities under one roof

Prime Location:

Located at Haji Ali Park, Mahalaxmi in Mumbai

Proximity to major commercial hubs and thriving residential colonies

Asset Light Engagement Framework:

Partnered with SRCC, an institution renowned for serving the needs of children from all sections of society

- Civil Infrastructure provided by the partner
- NH's investment only in medical equipment

Debut in Mumbai Healthcare Market:

Showcases NH's entry in the Mumbai region

 Mumbai to act as a hub for western cluster which has facilities currently in Ahmedabad, Jaipur, Raipur, Mahuva and Palanpur

Indian Healthcare Services Industry





Indian Healthcare Industry at a Glance

Sector Outlook:


- Indian healthcare market is expected to reach US\$280 bn by 2020, a CAGR of 23% between FY15-20E
- Hospital segment constitutes ~71% of the market
- Medical tourism to contribute 15-20% to hospital revenue by FY20 from 5-10% currently


Inadequate Infrastructure:

- Out-of-pocket expenditure on healthcare is ~61% the highest in the world
- 7 beds per 10,000 population vs global average of 26 beds
- 3% specialist physicians cater to rural areas which comprises
 >70% of population

Growth Prospects:

- India's per capita income is expected to register a CAGR of 11% between FY16-21E
- Deaths due to NCDs are expected to be 74% of total deaths in 2030 compared with 60% in 2012
- <20% population has health insurance, INR 20/day premiums for coverage of INR 0.5mn are available</p>





Source: Financial analysts' brokerage reports



Key Growth Drivers

National Health Policy 2017 has set Ambitious Targets:

Universal healthcare coverage - Increase health expenditure as a percentage of GDP from the existing 1.15 % to 2.50 % by 2025

Demand Outstrips Supply:

 \sim 1.7mn beds required to meet India's healthcare needs by 2025

More Lifestyle Centric Diseases and Rising Urbanisation:


35% cardiovascular-ailment related share in incidents of death by 2030 compared with 31% in 2015


Share of Older Population to Rise:

27% of total population will fall in 45-60+ age group by 2021 from 22% in 2011

India's Recognition at World Stage in Healthcare Solutions:

Tertiary care facilities at lower cost with ease in visa procurement to drive patients from South East Asia and Middle East





Source: Financial analysts' brokerage reports

Operational Review





Key Highlights – Q4 FY17



Clinical and Operational

- Narayana Institute of Cardiac Sciences, Bengaluru, became the first hospital in the country to introduce a new smartgeneration catheter device that will correct electrical signals causing disturbance in the heart rhythm
- Da Vinci Robotic Surgical System, installed at Mazumdar Shaw Medical Centre, Bengaluru, crossed the milestone of performing more than 150 surgeries within 10 months of its commissioning
- Narayana Multispeciality Hospital, Raipur, performed the first Leadless Pacemaker Implant across Central India
- The facility at Cayman Islands showcased exemplary performance achieving an EBITDA margin of 13.3% in Q4 FY17 translating to 7.6% EBITDA margin for the year. The unit achieved this feat within 3 years of its operations
- NH entered into an agreement for healthcare services with ~300 capacity bedded Dharamshila Hospital & Research Centre to mark its maiden foray in NCR





#1 CANCER CARE HOSPITAL
IN EASTERN INDIA

Narayana Superspeciality Hospital, Howrah



Centre of Excellence in Emergency Medicine

Narayana Superspeciality Hospital, Howrah



Green Hospital


Narayana Multispeciality Hospital, Mysore




- Operating revenue of INR 4,835 mn in Q4 FY17, an increase of 13.1% YoY translating into INR 18,782 mn in FY17, an increase of 16.4% YoY
- Q4 FY17 YoY growth in EBITDA by 23.4% to INR 659 mn and FY17 YoY growth in EBITDA by 30.2% to INR 2,463 mn, reflecting an EBITDA margin of 13.6% in Q4 FY17 and 13.1% in FY17 respectively
- FY17 PAT after minority interest and share in loss of associates at INR 831 mn reflecting YoY growth of 291.3%
- Net debt of INR 1,826 mn as on 31st March, 2017, reflecting net debt to equity ratio of 0.19

Strong Momentum across All Growth Levers





INR mn 7.6 5.8 6.4 FY15 FY16 FY17



Second Largest * **Healthcare Operator**

- Consolidation of operations across existing units underpinning addition to capacity
- Calibrated focused expansion across geographies of interest

Steady Rise in ARPOB

- Improved case-mix and emphasis on cutting edge surgical procedures
- Increased share of international patients

Consistent Improvement in ALOS

- Evolving case-mix driving shorter stay procedures
- Continuous monitoring of operations

^{*} By operational bed count as of 1st May 2017


⁽¹⁾ Includes Managed beds, Cayman unit; FY17 figures includes 145 beds of Jammu facility, 190 beds of Dharamshila facility and 101 beds of SRCC facility, FY16 figures includes 65 beds of Berhampore, 195 beds of Hyderabad, 26 beds of Suguna which were closed later, FY15 includes 50 beds of Berhampore, 305 beds of Hyderabad, 26 beds of Suguna, 19 beds of Kuppam which were closed later


⁽²⁾ Excludes Managed Hospitals, Cayman facility, MMRHL, Berhampore, Hyderabad, Suguna and Kuppam facilities


⁽³⁾ Excludes Managed Hospitals, Cayman facility; excludes MMRHL for FY15 and FY16




Revenue Mix FY17: Strong Track Record of Topline Growth















- (1) FY13, FY15 figures are as per IGAAP and FY17 figure is as per IND AS
- (2) NH owns the P&L responsibility
- (3) Includes managed hospitals, clinics, learning and development, teleradiology, etc
- (4) As percentage of IP and OP revenue: Schemes include CGHS, ESIS, other state government schemes. Excludes Jammu unit, E City, Sarjapur, Hosur, HSR clinics and Berhampore unit
- (5) Includes Insurance-covered patients, corporate patients (including public sector undertakings)
- (6) Calculated on operating revenue of owned / operated hospitals
- (7) Others include hospitals at Jaipur, Raipur, Ahmedabad and newly commissioned facility at Kakriyal, Jammu
- (8) Calculated on IP revenue; 6 core specialities (cardiac sciences, renal sciences, oncology, neurosciences, gastroenterology and orthopaedics) account for ~88% of IP revenue in FY17 (excludes Kakriyal, Jammu unit)



Leadership across Karnataka & Eastern Clusters with Emerging Presence across Northern and Western Regions

As of 31st March 2017, for the period FY17



⁽¹⁾ Includes Managed hospitals and excludes Cayman facility

⁽²⁾ Excludes Managed hospitals and Cayman facility


⁽³⁾ Karnataka and Eastern clusters include 1 managed hospital each while Others include 2 managed hospitals

⁽⁴⁾ Occupancy is calculated on Census beds; ; Occupancy of 53% for Karnataka cluster, 57% for Eastern cluster and 47% for Others respectively on total operational beds

⁽⁵⁾ Does not include Berhampore hospital data as NH exited from it in November 2016



Matured Units Continue to show Steady Growth complementing Ramp Up of Newer Units



⁽²⁾ Includes Managed hospitals and excludes Cayman facility

⁽³⁾ Excludes Managed hospitals and Cayman facility

⁽⁴⁾ EBITDA before rental/revenue share and before allocation of any corporate expenses

⁽⁵⁾ Occupancy is calculated on Census beds; Occupancy of 56% for > 5 years bucket, 47% for 3-5 years, 43% for < 3 years, 56% for

⁻ Over 5 years include NICS,MSMC, RTIICS, units at Jaipur, Jamshedpur, Raipur and 2 other units at Kolkata viz. RTSC, RNN

^{- 3-5} years include units at Ahmedabad, Mysore, Whitefield, HSR, Guwahati and Shimoga

⁻ Less than 3 years include 4 managed hospitals and 1 unit at Kakriyal


⁻ Acquired facilities include 2 units of MMRHL, Kolkata and unit at Barasat (Kolkata)

Financial Review




Operating Leverage coupled with Cost Efficiencies boosting the Margins

Profitability Snapshot⁽¹⁾







- FY17 EBITDA grew by 30.2% YoY, reflecting an improvement of 139 bps in margin
- Heart Centres' revenues grew at 14.4% YoY and clocked an EBITDAR margin of 18.6%⁽²⁾ in FY17
- Hospital at Cayman Islands achieved operating revenue of US\$32.6 mn (113.4% YoY growth) and EBITDA of US\$2.5 mn in FY17

Overheads

Consumable Expenses

Employee + Doctors' expenses

⁽¹⁾ FY15 figures are as per IGAAP and FY16, FY17 figures are as per IND AS

⁽²⁾ EBITDA before rental/revenue share and before allocation of any corporate expenses

⁽³⁾ Categories have been calculated as Consumable Expenses = Purchase of medical consumables, drugs and surgical equipment, net of changes in inventories of medical consumables, drugs and surgical equipment; Employee and Doctors expenses = Employee benefits + Professional fees to doctors; Overheads = all other expenses



Consolidated Financial Performance

Figures in INR mn, unless stated otherwise

Profit and Loss Statement(1)

Particulars	Q4 FY16	Q4 FY17	FY16	FY17
Total Operating Revenue	4,276	4,835	16,138	18,782
Purchase of medical consumables, drugs and surgical equipment- Net of change in Inventory	1,025	1,084	3,871	4,359
Employee (Excluding Doctors) Expenses	780	839	3,025	3,395
Doctors Expenses	934	1,102	3,522	4,213
Other Admin Expenses	1,044	1,209	3,974	4,526
Total Expenses	3,784	4,234	14,393	16,493
Other Income	42	57	147	175
EBITDA	534	659	1,893	2,463
Depreciation and Amortization	212	212	761	799
Finance Costs	64	56	294	218
Profit Before Tax & Exceptional Items	257	391	837	1,446
Exceptional Items	96	0	110	13
Tax Expense	77	150	301	524
PAT before MI and share of loss of associates	85	241	426	909
Share in (loss) of associates and MI	-34	-18	-217	-79
PAT after MI and share in loss of associates	50	223	212	831
Total Comprehensive Income, net of tax	41	221	204	831

Key Balance Sheet Items(1)

Particulars	31st Mar 2016	31 st Mar 2017
Shareholder Equity	8,763	9,633
Total Debt	2,575	2,167
Long term debt	2,129	2,077
Short term debt	446	90
Net Block	9,927	10,209 ⁽²⁾
Goodwill	590	581
Non-current Investment	872	931
Net receivables	1,518	1,569
Cash and cash equivalents	241	341

As on March 31st, 2017, the consolidated net debt was Rs 1,826 mn representing a net debt to equity ratio 0.19

⁽¹⁾ Figures might not equal the reported numbers due to rounding off


⁽²⁾ Net Block includes non-cash government grant provision of Rs 1,448 mn

Shareholding Pattern

Shareholding as on 31st March 2017⁽¹⁾

Total Number of Shares

204,360,804



⁽¹⁾ Percentages might not add up to 100% due to rounding off

⁽²⁾ Includes 2.8% held by NHAPL (Narayana Health Academy Private Limited)

⁽³⁾ PE investors include CDC, Asia Growth Capital and JP Morgan who have been shareholders prior to the IPO



Thank you